An independent FDA advisory panel is meeting today to decide whether a cell therapy should be recommended for approval to treat the heart disease that has become the leading cause of death in Duchenne muscular dystrophy. Two days before the meeting, the FDA published a briefing document saying the pivotal trial did not show the therapy works.
The Cellular, Tissue, and Gene Therapies Advisory Committee convened at 9:30 a.m. Eastern at the FDA's White Oak campus in Silver Spring, Maryland, and the session is being livestreamed. The product is deramiocel, an investigational cell therapy from Capricor, Inc., submitted under Biologics License Application 125842 for the treatment of cardiomyopathy in male patients with Duchenne muscular dystrophy.
For roughly 15,000 Americans living with Duchenne and the families caring for them, this matters for a specific reason. There is currently no approved therapy for the heart component of the disease, and heart disease is what most patients now die from.
Why the Heart Became the Central Problem in Duchenne
Duchenne is a rare, X-linked genetic condition affecting about 1 in 3,500 boys, caused by the absence of functional dystrophin. Without that protein, skeletal and cardiac muscle weaken progressively.
Decades ago, most patients died in late adolescence or their early twenties, often from respiratory failure. According to the FDA briefing document, median life expectancy has since risen to roughly 30 years, with some patients living into their fourth decade, largely because respiratory and cardiac management improved.
That progress changed what patients die of. Dilated cardiomyopathy and cardiac conduction abnormalities are now the primary causes of death in Duchenne, according to the agency's review.
The treatment gap is real, and the FDA acknowledges it directly. No therapy has been approved for Duchenne cardiomyopathy. Clinicians borrow drugs developed for heart failure in the general population, including ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and beta blockers. Evidence for those drugs in Duchenne comes from relatively small studies. The eight FDA-approved Duchenne drugs were approved based on skeletal muscle measures, and their effect on the heart is unknown.
Cardiac damage in Duchenne is also hard to catch early. Because skeletal weakness limits activity, patients often do not develop the shortness of breath, fatigue, or dizziness that signal cardiomyopathy in others. Imaging is the main monitoring tool, and abnormalities typically first appear around age 14.
What the FDA Reviewers Concluded
The committee has one voting question: whether the evidence from the HOPE-3 study provides substantial evidence of effectiveness for deramiocel in Duchenne cardiomyopathy.
HOPE-3 was a randomized, double-blind, placebo-controlled, 12-month trial enrolling 106 males aged 10 to 22 at multiple sites. Fifty-four received deramiocel and 52 received placebo. About 85 percent were non-ambulatory. Mean age was roughly 15, and mean left ventricular ejection fraction at baseline was 57 percent, which is within the normal range.
The FDA's assessment is blunt. "The study did not meet its pre-specified primary and secondary efficacy endpoints," the briefing document states.
Using the analysis plan written before the trial began, the difference between groups on the primary measure of upper limb function was 0.66 points, with a confidence interval crossing zero and a p-value of 0.24. On the key cardiac measure, change in ejection fraction, the difference was 0.04 percentage points with a p-value of 0.97.
The dispute is about which analysis plan counts. After the blinded phase ended in June 2025, the sponsor produced two further versions of the statistical analysis plan. The version the company treats as final was dated one day before the database was locked and the data unblinded. Under that plan, the primary endpoint was redefined as percent change rather than point change, and the cardiac endpoint became a ranked change. Analyzed that way, the primary comparison reached a p-value of 0.029.
FDA reviewers wrote that those changes were not scientifically justified and treated the resulting analyses as post-hoc and exploratory. They also noted that the revised cardiac analysis excluded 23 randomized subjects, about 22 percent of the trial population, and that two placebo patients drove much of the shift in results.
Reviewers raised a further concern about blinding. Hypersensitivity reactions occurred in 22 of 53 deramiocel patients, or 41.5 percent, compared with 8 of 52 placebo patients, or 15.4 percent. Eleven placebo patients developed such reactions only after starting open-label treatment. Under those conditions, the agency wrote, plan changes made after data collection carry a high risk of being data-driven.
The Company's Response
Capricor rejects that framing. In a statement issued July 27, the company said its results are governed by the final analysis plan, which it says was finalized before unblinding, and that the FDA's analyses rely on an earlier version the company describes as "an unsigned incomplete internal draft."
The company has said publicly that HOPE-3 met its primary endpoint, its key secondary cardiac endpoint, and all error-controlled secondary endpoints.
Readers should understand what is and is not settled. This is a documented disagreement between a regulator and a sponsor about statistical methods, not a safety scandal and not a finding that the therapy is harmful. The FDA's own briefing document carries a disclaimer stating that reviewer conclusions do not necessarily represent the agency's final position, and that no final determination will be issued until the committee's input is considered and all reviews are complete.
The original application, based on the earlier HOPE-2 study, received a Complete Response Letter last year for lack of substantial evidence of effectiveness. The FDA resumed review after the company submitted HOPE-3 data.
What Families Should Take from Today and What Comes Next
Nothing about today's meeting changes any patient's current treatment. Deramiocel is investigational and not available by prescription. Families should not stop, start, or alter cardiac medications based on this news, and questions about a specific child's heart monitoring belong with that child's cardiologist and neuromuscular team.
Advisory committee recommendations are non-binding. The FDA generally follows them but is not required to. The company's target action date for a decision is August 22, 2026.
The panel is being asked two discussion questions alongside the vote, both centered on whether the cardiac imaging results, considered with the earlier HOPE-2 data, support a conclusion that the therapy slows cardiac decline.
One further open item: FDA inspections of the sponsor were still underway when the briefing document was prepared. Preliminary findings noted that statistical work moved from an outside vendor to an in-house team during the trial, a departure from the approved blinding plan.
The newest confirmed fact is that the FDA's reviewers do not believe HOPE-3 demonstrated effectiveness, and that the sponsor disputes the basis for that conclusion. The people most affected are families managing Duchenne cardiomyopathy with no approved option. The most reasonable action is to watch for the committee vote and the August decision rather than drawing conclusions from either side's characterization. The central uncertainty is whether the panel accepts the agency's reading of the analysis plan, and whether the FDA follows the panel either way.
Frequently Asked Questions
What is deramiocel? An investigational cell therapy made from cells derived from donor hearts, given as an intravenous infusion every three months. It is not approved and is not available by prescription.
What is the committee voting on? Whether evidence from the HOPE-3 study provides substantial evidence of effectiveness for deramiocel in the treatment of cardiomyopathy in Duchenne muscular dystrophy.
Does an advisory committee vote decide approval? No. The committee makes a non-binding recommendation. The FDA generally follows such recommendations but is not legally required to, and will issue its own decision after completing its review.
Why is heart disease the focus rather than muscle weakness? As respiratory care improved and life expectancy rose to roughly 30 years, dilated cardiomyopathy and conduction abnormalities became the primary causes of death in Duchenne.
Are there approved treatments for Duchenne cardiomyopathy now? No. Clinicians use standard heart failure medications developed for the general population, supported by relatively small studies in Duchenne patients.
What did the trial actually find? Under the analysis plan written before the trial, neither the primary upper limb measure nor the cardiac measure showed a statistically significant difference. Under a later plan created by the sponsor, the primary comparison reached statistical significance.
When will there be a decision? The company has stated a target action date of August 22, 2026. MedicalDaily will report the committee vote and the FDA decision when issued.
